LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | A443654 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 1118 | 3694 | 0.3027 | -0.1616 |
| SK-BR-3 | OSI-027 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 1909 | 3694 | 0.5169 | 0.1951 |
| SK-BR-3 | XMD11-85h | 0.37 | uM | LJP6 | 72 | hr | 1476 | 2994 | 3694 | 0.8107 | 0.6846 |
| SK-BR-3 | HG-6-64-01 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 3252 | 3694 | 0.8805 | 0.8009 |
| SK-BR-3 | WH-4-025 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3321 | 3694 | 0.8991 | 0.8319 |
| SK-BR-3 | WZ-4-145 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 2062 | 3694 | 0.5584 | 0.2643 |
| SK-BR-3 | XMD16-144 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 1478 | 3694 | 0.4002 | 0.0007 |
| SK-BR-3 | Brivanib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3015 | 3694 | 0.8164 | 0.6941 |
| SK-BR-3 | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 1678 | 3694 | 0.4542 | 0.0908 |
| SK-BR-3 | BX-912 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 1738 | 3694 | 0.4705 | 0.1178 |
| SK-BR-3 | Canertinib | 0.37 | uM | LJP6 | 72 | hr | 1476 | 1514 | 3694 | 0.4099 | 0.0168 |
| SK-BR-3 | Celastrol | 0.37 | uM | LJP6 | 72 | hr | 1476 | 1424 | 3694 | 0.3855 | -0.0238 |
| SK-BR-3 | CGP60474 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 1380 | 3694 | 0.3738 | -0.0433 |
| SK-BR-3 | CGP60474 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 999 | 3694 | 0.2704 | -0.2155 |
| SK-BR-3 | CHIR-99021 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 2945 | 3694 | 0.7974 | 0.6625 |
| SK-BR-3 | CP724714 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 1797 | 3694 | 0.4866 | 0.1448 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3773 | 3694 | 1.0216 | 1.0359 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 2825 | 3694 | 0.7647 | 0.6081 |
| SK-BR-3 | Momelotinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 2957 | 3694 | 0.8007 | 0.6679 |
| SK-BR-3 | Dasatinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3598 | 3694 | 0.9742 | 0.9570 |
| SK-BR-3 | Dasatinib | 0.37 | uM | LJP6 | 72 | hr | 1476 | 3633 | 3694 | 0.9837 | 0.9728 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 2511 | 3694 | 0.6799 | 0.4668 |
| SK-BR-3 | Enzastaurin | 0.37 | uM | LJP5 | 72 | hr | 1476 | 4089 | 3694 | 1.1070 | 1.1783 |
| SK-BR-3 | Erlotinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3425 | 3694 | 0.9273 | 0.8788 |
| SK-BR-3 | Foretinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 1525 | 3694 | 0.4129 | 0.0219 |